AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 7:30 a.m. Pacific Time.
The presentation and Q&A session will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section.
About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
